Literature DB >> 8752155

Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells.

C De Giovanni1, L Landuzzi, F Frabetti, G Nicoletti, C Griffoni, I Rossi, M Mazzotti, L Scotto, P Nanni, P L Lollini.   

Abstract

Human rhabdomyosarcoma cells express membrane epidermal growth factor receptor (ECF-R), which could confer responsiveness to EGF and transforming growth factor-alpha (TGF-alpha) of autocrine or paracrine origin. To study the role played by this growth factor circuit in the proliferation and differentiation of myogenic neoplastic cells, human rhabdomyosarcoma EGF-R-expressing cells (RD/18 clone) have been transfected with a plasmid containing a fragment of the EGF-R cDNA in the antisense orientation. In vitro growth and differentiative ability were studied on six antisense-transfected clones (AS) in comparison to parental RD/18 cells and to cells transfected with the plasmid containing only the neomycin resistance gene (NEO). A reduced EGF-R membrane expression was found in AS clones by decreased immunofluorescence with an anti-EGF-R monoclonal antibody. All AS transfectants had a greatly impaired proliferative ability, even when cultured in fetal bovine serum-containing medium. Proliferation of AS clones was completely blocked in medium supplemented with 2% horse serum. The differentiation ability of AS clones was heterogeneous, ranging from clones with a percentage of myosin-positive cells higher than controls to clones with a negligible myosin expression. Therefore, the growth impairment determined by the loop interruption is not sufficient to switch on the differentiation program. The role played by EGF-R in the proliferation of human rhabdomyosarcoma cells suggests that this receptor could constitute a target for a therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752155

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Authors:  Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

Review 2.  Signal transduction pathways and their relevance in human astrocytomas.

Authors:  M M Feldkamp; N Lau; A Guha
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

3.  Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.

Authors:  Valerie A Granados; Usha Avirneni-Vadlamudi; Pooja Dalal; Samuel R Scarborough; Kathleen A Galindo; Priya Mahajan; Rene L Galindo
Journal:  Cancer Res       Date:  2019-07-22       Impact factor: 12.701

4.  Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD.

Authors:  Hua Wang; Guang-Hua Yang; Hong Bu; Qiao Zhou; Li-Xin Guo; Shou-Li Wang; Lv Ye
Journal:  Int J Exp Pathol       Date:  2003-06       Impact factor: 1.925

5.  Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.

Authors:  Regina I Jakacki; Marta Hamilton; Richard J Gilbertson; Susan M Blaney; Jean Tersak; Mark D Krailo; Ashish M Ingle; Stephan D Voss; Janet E Dancey; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

6.  Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas.

Authors:  C Kersting; J Packeisen; B Leidinger; B Brandt; R von Wasielewski; W Winkelmann; P J van Diest; G Gosheger; H Buerger
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

Review 7.  Molecularly targeted therapy for pediatric brain tumors.

Authors:  Warren K E
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.506

8.  Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Authors:  Lisa E S Crose; Corinne M Linardic
Journal:  Sarcoma       Date:  2011-01-02

9.  The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.

Authors:  N Iizuka; K Hirose; T Noma; S Hazama; A Tangoku; H Hayashi; T Abe; K Yamamoto; M Oka
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  DCX and CRABP2 are candidate genes for differential diagnosis between pre-chemotherapy embryonic and alveolar rhabdomyosarcoma in pediatric patients.

Authors:  Nian Sun; Yeran Yang; Shengcai Wang; Jie Zhang; Jingang Gui; Jun Tai; Lejian He; Jiatong Xu; Yanzhen Li; Xuexi Zhang; Qiaoyin Liu; Zhiyong Liu; Yongli Guo; Xin Ni
Journal:  Pediatr Investig       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.